Liping Wang1, Fangzheng Han2, Hualing Duan3, Fang Ji4, Xuebing Yan5, Yuchen Fan6, Kai Wang7. 1. Qilu Hospital of Shandong University, Shandong, China. 163wangliping@163.com. 2. Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. hfz633193@163.com. 3. Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. 2206391588@qq.com. 4. Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. 2572082612@qq.com. 5. Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. yxbxuzhou@126.com. 6. Qilu Hospital of Shandong University, Shandong, China. pyfanyuchen@126.com. 7. Qilu Hospital of Shandong University, Shandong, China. wangdoc2010@163.com.
Abstract
INTRODUCTION: Previous studies have indicated that the drug-resistant mutations of hepatitis B virus (HBV) are a major obstacle to antiviral therapy. However, it is still unclear whether there are pre-existent resistance mutations in patients with HBV infection and the relationship between drug-resistant mutation, genotypes, and progression of hepatitis B disease. METHODOLOGY: A total of 357 treatment-naïve patients with HBV infection were involved in this retrospective study. The drug-resistant mutations of HBV reverse transcriptase domain were screened by direct gene sequencing. RESULTS: Lamivudine (LAM) resistance was detected in 8 patients (3.7%) with chronic hepatitis B (CHB), 13 (11.7%) patients with liver cirrhosis (LC), and 6 (21.4%) patients with hepatocellular carcinoma (HCC). Adefovir(ADV)-resistant mutations were detected in 10 (4.6%) patients with CHB, 15 (13.5%) patients with LC and 4 (14.5%) patients with HCC. Both LAM and ADV resistant mutations were detected in 2 patients (0.9%) with CHB, 1 patient (0.9%) with LC and 1 patient (3.6%) with HCC. Significant differences (p <0.01) were observed in the drug-resistance rates among patients with CHB, LC and HCC. Meanwhile, all the drug-resistant mutations were found in patients with HBV genotype C. CONCLUSIONS: This study demonstrated higher risk of pre-existing drug-resistant mutations in patients with HBV genotype C comparing to patients with HBV genotype B. Likewise, increasing prevalence of pre-existing drug-resistant mutations was shown, alongside with the progression of the disease. Copyright (c) 2017 Liping Wang, Fangzheng Han, Hualing Duan, Fang Ji, Xuebing Yan, Yuchen Fan, Kai Wang.
INTRODUCTION: Previous studies have indicated that the drug-resistant mutations of hepatitis B virus (HBV) are a major obstacle to antiviral therapy. However, it is still unclear whether there are pre-existent resistance mutations in patients with HBV infection and the relationship between drug-resistant mutation, genotypes, and progression of hepatitis B disease. METHODOLOGY: A total of 357 treatment-naïve patients with HBV infection were involved in this retrospective study. The drug-resistant mutations of HBV reverse transcriptase domain were screened by direct gene sequencing. RESULTS:Lamivudine (LAM) resistance was detected in 8 patients (3.7%) with chronic hepatitis B (CHB), 13 (11.7%) patients with liver cirrhosis (LC), and 6 (21.4%) patients with hepatocellular carcinoma (HCC). Adefovir(ADV)-resistant mutations were detected in 10 (4.6%) patients with CHB, 15 (13.5%) patients with LC and 4 (14.5%) patients with HCC. Both LAM and ADV resistant mutations were detected in 2 patients (0.9%) with CHB, 1 patient (0.9%) with LC and 1 patient (3.6%) with HCC. Significant differences (p <0.01) were observed in the drug-resistance rates among patients with CHB, LC and HCC. Meanwhile, all the drug-resistant mutations were found in patients with HBV genotype C. CONCLUSIONS: This study demonstrated higher risk of pre-existing drug-resistant mutations in patients with HBV genotype C comparing to patients with HBV genotype B. Likewise, increasing prevalence of pre-existing drug-resistant mutations was shown, alongside with the progression of the disease. Copyright (c) 2017 Liping Wang, Fangzheng Han, Hualing Duan, Fang Ji, Xuebing Yan, Yuchen Fan, Kai Wang.
Entities:
Keywords:
hepatitis B virus; mutation; pre-existing drug resistance; reverse transcriptase; three